Abstract
The deregulated proteolysis is associated with various diseases in humans. Proteases are commonly regarded as the therapeutic targets. Almost one-third of all proteolytic enzymes in humans are serine proteases. This work provides a brief characteristic of the proteinaceous natural inhibitors, mostly of serine proteases. The examples of some classical and recently identified canonical and noncanonical inhibitors as well as serpins are described. Their actual and potential therapeutic applications are discussed.
Keywords: Serine proteases, canonical, non-canonical inhibitors, serpins.
Current Pharmaceutical Design
Title:Natural Proteinaceous Inhibitors of Serine Proteases
Volume: 19 Issue: 6
Author(s): Dawid Debowski
Affiliation:
Keywords: Serine proteases, canonical, non-canonical inhibitors, serpins.
Abstract: The deregulated proteolysis is associated with various diseases in humans. Proteases are commonly regarded as the therapeutic targets. Almost one-third of all proteolytic enzymes in humans are serine proteases. This work provides a brief characteristic of the proteinaceous natural inhibitors, mostly of serine proteases. The examples of some classical and recently identified canonical and noncanonical inhibitors as well as serpins are described. Their actual and potential therapeutic applications are discussed.
Export Options
About this article
Cite this article as:
Debowski Dawid, Natural Proteinaceous Inhibitors of Serine Proteases, Current Pharmaceutical Design 2013; 19 (6) . https://dx.doi.org/10.2174/138161281906140714121225
DOI https://dx.doi.org/10.2174/138161281906140714121225 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Reviewing the Cardiovascular Complications of HIV Infection After the Introduction of Highly Active Antiretroviral Therapy
Current Drug Targets - Cardiovascular & Hematological Disorders Antiplatelet Therapy in Children: Why So Different from Adults’?
Current Pharmaceutical Design Filariasis: Current Status, Treatment and Recent Advances in Drug Development
Current Medicinal Chemistry Hypersensitivity Reactions to Non-Steroidal Anti-Inflammatory Drugs
Current Pharmaceutical Design Inflammation-Mediating Proteases: Structure, Function in (Patho) Physiology and Inhibition
Protein & Peptide Letters Safety of Dipeptidyl Peptidase 4 Inhibitors for Treatment of Type 2 Diabetes
Current Drug Safety Peptide Metabolism and the Control of Body Fluid Homeostasis
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Aluminum Vaccine Adjuvants: Are they Safe?
Current Medicinal Chemistry Adverse Drug Reaction Labelling for Atomoxetine, Methylphenidate and Modafinil: Comparison of Product Information for Oral Formulations in Australia, Denmark and the United States
Current Drug Safety Phenolics Constituents of Different Types of Propolis and their Antimicrobial Activities
Anti-Infective Agents Hypersensitivity to Aspirin and Other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
Current Pharmaceutical Design Methylene Blue and Vasoplegia: Who, When, and How?
Mini-Reviews in Medicinal Chemistry Pharmacogenomics of Asthma
Current Pharmaceutical Design Nephroangiosclerosis and Its Pharmacological Approach
Current Vascular Pharmacology Structure Based Drug Design of Angiotensin-I Converting Enzyme Inhibitors
Current Medicinal Chemistry Treatment for Diabetic Peripheral Neuropathy: What have we Learned from Animal Models?
Current Diabetes Reviews Cow’s Milk Allergy: Where have we Come from and where are we Going?
Endocrine, Metabolic & Immune Disorders - Drug Targets Novel Agents Aiming at Specific Molecular Targets Increase Chemosensitivity and Overcome Chemoresistance in Hematopoietic Malignancies
Current Pharmaceutical Design Seasonal Allergic Rhinitis
Recent Patents on Inflammation & Allergy Drug Discovery Serum Sickness Reaction to Rituximab with Positive Immediate Intradermal Skin Test: A Case Report
New Emirates Medical Journal